Literature DB >> 1622177

Effects of immunoglobulin G and low-dose amphotericin B on Candida albicans infections in burned mice.

A N Neely1, I A Holder.   

Abstract

Candidiasis causes serious problems for compromised hosts. Effective treatments for Candida albicans infections are few. To see if immunoglobulin (Ig) therapy could be beneficial, burn-immunocompromised mice were treated intravenously with 2.5 mg of five different IgG preparations 48 h postburn and post-C. albicans challenge. Despite up to fourfold differences in titer (1:1,600 to 1:6,400) to C. albicans, all preparations improved 10-day survival about 30% (P less than 0.0001). Treatment with a low dose of amphotericin B (AmB; 0.09 mg/kg of body weight) intravenously 24 and 48 h after burn and challenge improved survival 9 to 45% (P less than 0.0001). Treatment with a low dose of AmB plus IgG showed the same results as treatment with AmB alone and better results than treatment with IgG alone. Quantitative renal cultures from burned mice treated with AmB plus one IgG preparation, Sandoglobulin, showed that C. albicans counts decreased in sham-treated mice from 7.21 +/- 0.15 log10 CFU/g (mean +/- standard error of the mean) to 5.31 +/- 0.34, which was significantly less than counts with AmB (6.11 +/- 0.35) or Sandoglobulin (6.39 +/- 0.18) treatment alone. We conclude that (i) by using decreases in mortality and in renal fungal load as end points, treatment with IgG preparations alone or with a low dose of AmB alone protected burn-immunocompromised mice from candidiasis; (ii) though AmB plus one IgG preparation significantly decreased renal fungal load, the combination did not significantly decrease mortality beyond that found with AmB alone; and (iii) survival data did not correlate with IgG titers to C. albicans.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622177      PMCID: PMC190571          DOI: 10.1128/AAC.36.3.643

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  The capacity of various types of immunoglobulin for intravenous use to interact with Fc receptors of human monocytes and macrophages.

Authors:  T W Jungi; J Eiholzer; P G Lerch; S Barandun
Journal:  Blut       Date:  1986-10

2.  Phagocytosis by human monocytes.

Authors:  M J Cline; R I Lehrer
Journal:  Blood       Date:  1968-09       Impact factor: 22.113

3.  The effect of thermal injury on serum immunoglobulins.

Authors:  A M Munster; H C Hoagland; B A Pruitt
Journal:  Ann Surg       Date:  1970-12       Impact factor: 12.969

4.  Intravenous immune globulin: a cautionary note.

Authors:  A S Cross; B M Alving; J C Sadoff; P Baldwin; H Terebelo; D Tang
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

5.  Synergy between acylureidopenicillins and immunoglobulin G in experimental animals.

Authors:  A Dalhoff
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

6.  Replacement therapy with modified immunoglobulin G in burn patients: preliminary kinetic studies.

Authors:  K Z Shirani; G M Vaughan; A T McManus; B W Amy; W F McManus; B A Pruitt; A D Mason
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

7.  Acute non-specific inflammatory reactions and protection against experimental Candida albicans infection.

Authors:  E Drouhet; B Dupont; M Pelletier; J P Giroud
Journal:  Agents Actions       Date:  1981-12

8.  Comparative opsonic activity of intravenous gamma globulin preparations for common bacterial pathogens.

Authors:  H R Hill; N H Augustine; A O Shigeoka
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

9.  Immunologic responses to Candida albicans. III. Effects of passive transfer of lymphoid cells or serum on murine candidiasis.

Authors:  N N Pearsall; B L Adams; R Bunni
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

10.  Role of antibodies and effect of BCG vaccination in experimental candidiasis in mice.

Authors:  P K Maiti; A Kumar; R Kumar; L N Mohapatra
Journal:  Mycopathologia       Date:  1985-08       Impact factor: 2.574

View more
  1 in total

Review 1.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.